Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M163,906Revenue $M42,237Net Margin (%)28.2Z-Score3.8
Enterprise Value $M169,734EPS $4.1Operating Margin %13.4F-Score5
P/E(ttm))14.1Cash Flow Per Share $6.3Pre-tax Margin (%)40.9Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %5.4Quick Ratio1.5Cash flow > EarningsN
Price/Sales4.05-y EBITDA Growth Rate %4.0Current Ratio1.8Lower Leverage y-yY
Price/Cash Flow7.1y-y EBITDA Growth Rate %90.6ROA % (ttm)11.6Higher Current Ratio y-yN
Dividend Yield %3.1Insider Buy (3m)0ROE % (ttm)24.6Less Shares Outstanding y-yY
Payout Ratio %43.0Shares Outstanding M2,838ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKIrving Kahn 2014-12-31 Reduce-0.54%$53.43 - $61.88
($58.42)
$ 57.75-1%Reduce -5.08%1,052,807
MRKVanguard Health Care Fund 2014-12-31 Add0.32%$53.43 - $61.88
($58.42)
$ 57.75-1%Add 7.08%35,788,048
MRKJoel Greenblatt 2014-12-31 Add0.23%$53.43 - $61.88
($58.42)
$ 57.75-1%Add 94.88%1,045,652
MRKJean-Marie Eveillard 2014-12-31 Reduce-0.16%$53.43 - $61.88
($58.42)
$ 57.75-1%Reduce -99.16%9,050
MRKPRIMECAP Management 2014-12-31 Buy 0.04%$53.43 - $61.88
($58.42)
$ 57.75-1%New holding700,000
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 57.75-2%Add 323.00%536,550
MRKJean-Marie Eveillard 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 57.75-2%Reduce -38.25%1,083,826
MRKGeorge Soros 2014-09-30 Sold Out -0.04%$55.64 - $61.18
($58.89)
$ 57.75-2%Sold Out0
MRKRay Dalio 2014-09-30 Buy 0.01%$55.64 - $61.18
($58.89)
$ 57.75-2%New holding14,141
MRKKen Fisher 2014-06-30 Add0.7%$54.83 - $59.62
($57.16)
$ 57.751%Add 791.55%6,464,243
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 57.751%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 57.751%Reduce -10.01%35,960,137
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 57.751%Add 3456.04%126,844
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 57.751%Reduce -21.54%1,755,082
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 57.751%New holding86,800
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 57.751%Sold Out0
MRKIrving Kahn 2014-03-31 Reduce-2.88%$49.49 - $57.47
($54)
$ 57.756%Reduce -55.32%1,128,415
MRKBill Nygren 2014-03-31 Sold Out -0.69%$49.49 - $57.47
($54.09)
$ 57.756%Sold Out0
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 57.756%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 57.756%Reduce -18.11%39,959,196
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2015-02-18Sell5,164$58.67-1.82view
Deese Willie AExe V-P & Pres. MMD 2015-02-11Sell135,864$58.56-1.64view
WENDELL PETER CDirector 2015-02-09Sell5,000$58.76-1.97view
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.48-7.81view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.47-7.8view
FRAZIER KENNETH CChairman, President & CEO 2014-12-10Sell9,846$60-4view
Kuhlik Bruce NExe V-P & Gen Counsel 2014-12-08Sell50,000$62-7.1view
LAZARUS ROCHELLE BDirector 2014-11-26Sell10,000$59.63-3.4view
WEEKS WENDELL PDirector 2014-11-24Sell5,000$59.13-2.59view
FRAZIER KENNETH CChairman, President & CEO 2014-11-10Sell10,000$57.98-0.66view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
      Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
      Abner Herrman's Top Three Holdings Feb 26 2015 
      PRIMECAP Management's New Positions Feb 13 2015 
      The Dogs of the Dow Get Off to a Sluggish Start in 2015 Feb 11 2015 
      Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Irving Kahn Adds to Stakes in Three Companies in Q4 Feb 03 2015 
      World Economic Forum 2015 – What To Look Forward For Jan 18 2015 

      More From Our Partners
      Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog Mar 26 2015 - ZACKS

      More From Other Websites
      Europe pushes back verdict on Bristol immune system cancer drug Mar 27 2015
      Europe pushes back verdict on Bristol immune system cancer drug Mar 27 2015
      Europe postpones decision on Bristol immune system cancer drug Mar 27 2015
      Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28 Mar 27 2015
      Two Experimental Ebola Vaccines Show Promise Mar 26 2015
      Pressure's On Senate To Pass 'Doc Fix' In Latest Blow To Fee-For-Service Medicine Mar 26 2015
      MassBio panel tackles perils of drugs for bioterrorism and superbugs Mar 26 2015
      Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog Mar 26 2015
      Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes... Mar 26 2015
      Flagship Ventures, After A String Of IPOs, Gets $537M To Build More Biotech Startups Mar 26 2015
      Merck’s Self-Medication Is Welcome Mar 25 2015
      Cramer: Nasdaq's griddle too hot Mar 25 2015
      Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
      Merck Announces New $10 Billion Share Repurchase Program Mar 25 2015
      Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD):... Mar 25 2015
      Stocks plunge; Dow off 250 points, Nasdaq drops 2% Mar 25 2015
      Jim Cramer Sees American Express Unable to Challenge Visa, MasterCard Mar 25 2015
      4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary Mar 25 2015
      Guinea starts testing Merck vaccine in Ebola hotspots Mar 25 2015
      Merck increases share buyback plan Mar 25 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK